REGENEREX PHARMA, INC. Total Assets

• REGENEREX PHARMA, INC. showed an increase of +64.8% in Total Assets from 2024 to 2025.
• This data is from REGENEREX PHARMA, INC.'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
• XBRL data for this metric is available from 2010 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2011: $377.1 thousand | Q2 2012: $47.5 thousand | Q3 2012: $49.3 thousand | Q1 2014: $50.9 thousand | Q2 2014: $5.8 thousand | Q3 2014: $14.9 thousand | Q3 2017: $19.3 thousand | Q4 2017: $18.4 thousand | Q2 2018: $13.1 thousand | Q3 2018: $11.8 thousand | Q4 2018: $41.4 thousand | Q2 2019: $144.7 thousand | Q3 2019: $251.3 thousand | Q4 2019: $254.7 thousand | Q2 2020: $255.2 thousand | Q3 2020: $254.1 thousand | Q4 2020: $252.5 thousand | Q2 2021: $11.1 thousand | Q3 2021: $12.0 thousand | Q4 2021: $11.4 thousand | Q2 2022: $10.5 thousand | Q3 2022: $8.8 thousand | Q4 2022: $9.9 thousand | Q2 2023: $1.04 million | Q3 2023: $932.6 thousand | Q4 2023: $852.1 thousand | Q2 2024: $729.1 thousand | Q3 2024: $633.0 thousand | Q4 2024: $646.9 thousand | Q1 2025: $1.26 million | Q2 2025: $763.4 thousand | Q3 2025: $617.8 thousand.
• Over the full 13 years of available data (2010 to 2025), REGENEREX PHARMA, INC.'s Total Assets has grown by 19,983.2%.
• Historical annual values: Fiscal year 2025: $1.26 million | Fiscal year 2024: $766.7 thousand | Fiscal year 2023: $6.5 thousand | Fiscal year 2022: $15.3 thousand | Fiscal year 2021: $10.5 thousand | Fiscal year 2020: $259.2 thousand | Fiscal year 2019: $105.6 thousand | Fiscal year 2018: $15.1 thousand | Fiscal year 2014: $3.8 thousand | Fiscal year 2013: $51.0 thousand | Fiscal year 2012: $11.3 thousand | Fiscal year 2011: $76.8 thousand | Fiscal year 2010: $6.3 thousand.
• Data sourced from SEC EDGAR public filings as of August 4, 2026.

Last verified: August 4, 2026